These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 28651891)

  • 1. Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome.
    Roncacé V; Burattini C; Stagni F; Guidi S; Giacomini A; Emili M; Aicardi G; Bartesaghi R
    Neurobiol Dis; 2017 Oct; 106():89-100. PubMed ID: 28651891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
    Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GABA
    Gennaccaro L; Fuchs C; Loi M; Roncacè V; Trazzi S; Ait-Bali Y; Galvani G; Berardi AC; Medici G; Tassinari M; Ren E; Rimondini R; Giustetto M; Aicardi G; Ciani E
    Neurobiol Dis; 2021 Jun; 153():105304. PubMed ID: 33621640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: a model of Down syndrome.
    Harashima C; Jacobowitz DM; Witta J; Borke RC; Best TK; Siarey RJ; Galdzicki Z
    J Comp Neurol; 2006 Feb; 494(5):815-33. PubMed ID: 16374808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.
    Kleschevnikov AM; Belichenko PV; Faizi M; Jacobs LF; Htun K; Shamloo M; Mobley WC
    J Neurosci; 2012 Jul; 32(27):9217-27. PubMed ID: 22764230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infantile spasms in down syndrome: Rescue by knockdown of the GIRK2 channel.
    Joshi K; Shen L; Michaeli A; Salter M; Thibault-Messier G; Hashmi S; Eubanks JH; Cortez MA; Snead OC
    Ann Neurol; 2016 Oct; 80(4):511-21. PubMed ID: 27462820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Belichenko PV; Gall J; George L; Nosheny R; Maloney MT; Salehi A; Mobley WC
    Neurobiol Dis; 2012 Feb; 45(2):683-91. PubMed ID: 22062771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current.
    Best TK; Siarey RJ; Galdzicki Z
    J Neurophysiol; 2007 Jan; 97(1):892-900. PubMed ID: 17093127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome.
    Best TK; Cramer NP; Chakrabarti L; Haydar TF; Galdzicki Z
    Exp Neurol; 2012 Feb; 233(2):749-57. PubMed ID: 22178330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome.
    Costa AC; Grybko MJ
    Neurosci Lett; 2005 Jul; 382(3):317-22. PubMed ID: 15925111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships.
    Belichenko PV; Kleschevnikov AM; Salehi A; Epstein CJ; Mobley WC
    J Comp Neurol; 2007 Oct; 504(4):329-45. PubMed ID: 17663443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome.
    Belichenko PV; Kleschevnikov AM; Masliah E; Wu C; Takimoto-Kimura R; Salehi A; Mobley WC
    J Comp Neurol; 2009 Feb; 512(4):453-66. PubMed ID: 19034952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome.
    Giacomini A; Stagni F; Emili M; Guidi S; Salvalai ME; Grilli M; Vidal-Sanchez V; Martinez-Cué C; Bartesaghi R
    Brain Res Bull; 2018 Jun; 140():378-391. PubMed ID: 29935232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in cerebellar unipolar brush cells of a Down syndrome mouse model.
    Harashima C; Jacobowitz DM; Stoffel M; Chakrabarti L; Haydar TF; Siarey RJ; Galdzicki Z
    Cell Mol Neurobiol; 2006; 26(4-6):719-34. PubMed ID: 16783527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome.
    Scott-McKean JJ; Roque AL; Surewicz K; Johnson MW; Surewicz WK; Costa ACS
    Neural Plast; 2018; 2018():9235796. PubMed ID: 29849573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity-Dependent Dysfunction in Visual and Olfactory Sensory Systems in Mouse Models of Down Syndrome.
    William CM; Saqran L; Stern MA; Chiang CL; Herrick SP; Rangwala A; Albers MW; Frosch MP; Hyman BT
    J Neurosci; 2017 Oct; 37(41):9880-9888. PubMed ID: 28899917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of Potassium and Cation Channels in Hippocampal Abnormalities of Embryonic Ts65Dn and Tc1 Trisomic Mice.
    Stern S; Segal M; Moses E
    EBioMedicine; 2015 Sep; 2(9):1048-62. PubMed ID: 26501103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome.
    Stagni F; Magistretti J; Guidi S; Ciani E; Mangano C; Calzà L; Bartesaghi R
    PLoS One; 2013; 8(4):e61689. PubMed ID: 23620781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early environmental therapy rescues brain development in a mouse model of Down syndrome.
    Begenisic T; Sansevero G; Baroncelli L; Cioni G; Sale A
    Neurobiol Dis; 2015 Oct; 82():409-419. PubMed ID: 26244989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.